Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ$4.67
Market Cap
$211.17M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
921 of 924
Rank in Industry
527 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
YMAB Insider Trading Activity
YMAB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $4,151,837 | 13 | 100 |
Related Transactions
| Ber Gerard | director | 0 | $0 | 1 | $8,664 | $-8,664 |
| Rossi Michael J | PRESIDENT & CEO | 0 | $0 | 1 | $20,368 | $-20,368 |
| Wilms Joris | SVP & CHIEF OPERATING OFFICER | 0 | $0 | 1 | $73,450 | $-73,450 |
| Kruse Bo | EVP, CFO, SECRY & TREAS. | 0 | $0 | 2 | $723,055 | $-723,055 |
| Lund-Hansen Torben | SVP & CHIEF TECHNICAL OFFICER | 0 | $0 | 1 | $768,500 | $-768,500 |
| Gad Thomas | CHIEF BUSINESS OFFICER | 0 | $0 | 7 | $2.56M | $-2.56M |
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line …
Insider Activity of Y-mAbs Therapeutics, Inc.
Over the last 12 months, insiders at Y-mAbs Therapeutics, Inc. have bought $0 and sold $4.15M worth of Y-mAbs Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Y-mAbs Therapeutics, Inc. have bought $1.44M and sold $26.94M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 109,318 shares for transaction amount of $765,075 was made by WG Biotech ApS (director) on 2023‑12‑11.
List of Insider Buy and Sell Transactions, Y-mAbs Therapeutics, Inc.
| 2025-03-07 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 10,810 0.0242% | $5.23 | $56,536 | -7.75% | |
| 2025-03-07 | Sale | Rossi Michael J | PRESIDENT & CEO | 3,917 0.0087% | $5.20 | $20,368 | -7.75% | |
| 2024-09-16 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 30,000 0.0671% | $12.97 | $389,100 | -23.75% | |
| 2024-09-13 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 65,000 0.143% | $13.47 | $875,550 | -27.47% | |
| 2024-08-28 | Sale | Lund-Hansen Torben | SVP & CHIEF TECHNICAL OFFICER | 50,000 0.112% | $15.37 | $768,500 | -32.55% | |
| 2024-08-26 | Sale | Wilms Joris | SVP & CHIEF OPERATING OFFICER | 5,000 0.0109% | $14.69 | $73,450 | -31.20% | |
| 2024-06-11 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 35,000 0.0797% | $12.00 | $420,000 | -2.58% | |
| 2024-06-10 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 35,000 0.0795% | $12.03 | $421,050 | -2.86% | |
| 2024-06-10 | Sale | Ber Gerard | director | 722 0.0016% | $12.00 | $8,664 | -2.86% | |
| 2024-05-31 | Sale | Kruse Bo | EVP, CFO, SECRY & TREAS. | 31,371 0.0713% | $12.07 | $378,648 | -2.40% | |
| 2024-05-30 | Sale | Kruse Bo | EVP, CFO, SECRY & TREAS. | 28,629 0.0653% | $12.03 | $344,407 | -1.50% | |
| 2024-05-23 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 7,351 0.0176% | $13.00 | $95,563 | -4.03% | |
| 2024-05-21 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 25,000 0.0544% | $12.00 | $300,000 | -5.18% | |
| 2024-03-05 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 3,900 0.0088% | $16.44 | $64,116 | -26.35% | |
| 2024-03-05 | Sale | Smith Susan Laura | SVP & CHIEF COMMERCIAL OFFICER | 1,682 0.0038% | $16.55 | $27,837 | -26.35% | |
| 2024-03-05 | Sale | Rajah Vignesh | SVP & CHIEF MEDICAL OFFICER | 1,711 0.0039% | $16.53 | $28,283 | -26.35% | |
| 2023-12-15 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.1144% | $6.61 | $330,500 | +96.00% | |
| 2023-12-14 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.113% | $6.83 | $341,500 | +87.84% | |
| 2023-12-13 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.1109% | $6.58 | $329,000 | +89.42% | |
| 2023-12-11 | WG Biotech ApS | director | 109,318 0.2637% | $7.00 | $765,075 | +94.82% |
Total: 197
*Gray background shows transactions not older than one year
Insider Historical Profitability
54.64%
| Wedell-Wedellsborg Johan | director | 4559233 10.0827% | $21.29M | 7 | 17 | +87.41% |
| WG Biotech ApS | director | 4559233 10.0827% | $21.29M | 7 | 8 | +87.41% |
| HEALY JAMES | director | 2194278 4.8526% | $10.25M | 2 | 0 | +8.58% |
| TYAGI ASHU | director | 1392740 3.08% | $6.5M | 1 | 0 | <0.0001% |
| Moller-San Pedro Claus Juan | Chief Executive Officer | 607303 1.343% | $2.84M | 2 | 4 | +58.04% |
Historical Insider Profitability vs. Competitors
$7,150,333 | 87 | -8.28% | $207.01M | |
$21,540,805 | 87 | 0.99% | $217.93M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$613,304,943 | 46 | 11.85% | $191.55M | |
$48,218,096 | 42 | 0.89% | $204.72M |
YMAB Institutional Investors: Active Positions
| Increased Positions | 59 | +55.14% | 5M | +19.73% |
| Decreased Positions | 42 | -39.25% | 2M | -7.75% |
| New Positions | 20 | New | 3M | New |
| Sold Out Positions | 12 | Sold Out | 269,775 | Sold Out |
| Total Postitions | 124 | +15.89% | 29M | +11.97% |
YMAB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Paradigm Biocapital Advisors Lp | $23,554.00 | 9.41% | 4.24M | +150,000 | +3.67% | 2024-12-31 |
| Blackrock, Inc. | $16,672.00 | 6.66% | 3M | -26,763 | -0.89% | 2024-12-31 |
| Acorn Capital Advisors, Llc | $15,912.00 | 6.36% | 2.86M | +3M | New | 2024-12-31 |
| Sofinnova Investments, Inc. | $12,200.00 | 4.88% | 2.19M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $11,120.00 | 4.44% | 2M | -35,341 | -1.74% | 2024-12-31 |
| Polar Capital Holdings Plc | $10,180.00 | 4.07% | 1.83M | 0 | 0% | 2024-12-31 |
| Caligan Partners Lp | $9,830.00 | 3.93% | 1.77M | +572,729 | +47.92% | 2024-12-31 |
| State Street Corp | $7,308.00 | 2.92% | 1.31M | +104,628 | +8.65% | 2024-12-31 |
| Logos Global Management Lp | $5,560.00 | 2.22% | 1M | +200,000 | +25% | 2024-12-31 |
| Geode Capital Management, Llc | $4,572.00 | 1.83% | 822,309 | +8,820 | +1.08% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.